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ABSTRACT
Introduction: This paper describes a planned process
evaluation of the Use of a Multidrug Pill In Reducing
Cardiovascular Events (UMPIRE) trial, one of several
randomised clinical trials taking place globally to
assess the potential of cardiovascular drugs as a fixed-
dose combination (polypill) in cardiovascular disease
prevention. A fixed-dose combination may be a
promising strategy for promoting adherence to
medication; alleviating pill burden through simplifying
regimens and reducing cost. This process evaluation
will complement the UMPIRE trial by using qualitative
research methods to inform understanding of the
complex interplay of factors that underpin trial
outcomes.
Methods: A series of semistructured, in-depth
interviews with local health professionals and UMPIRE
trial participants in India and the UK will be
undertaken. The aim is to understand their views and
experiences of the trial context and of day-to-day use
of medications more generally. The grounded theory
approach will be used to analyse data and help inform
the processes of the UMPIRE trial.
Ethics and dissemination: The study has received
ethical approval for all sites in the UK and India where
trial participant interviews will be undertaken. The
process evaluation will help inform and enhance the
understanding of the UMPIRE trial results and its
applicability to clinical practice as well as shaping
policy regarding strategies for improving cardiovascular
medication adherence.
INTRODUCTION
Cardiovascular disease (CVD) is the leading
cause of death across the globe.1 There is an
enormous evidence base of proven effective
pharmacotherapeutic agents in secondary
prevention of CVD.2 3 However, worldwide
utilisation and persistence with such proven
drugs is low, especially in low-income and
middle-income countries (LMIC). The Single
Pill to Avert Cardiovascular Events (SPACE) col-
laboration is coordinating CVD ﬁxed-dose com-
bination (FDC) trials in several countries.4
The Use of a Multidrug Pill In Reducing cardio-
vascular Events (UMPIRE)5 trial is a prospect-
ive, randomised, open-label, blinded endpoint
(PROBE)6 clinical trial of a FDC-based treat-
ment strategy compared with usual care in par-
ticipants at high cardiovascular (CV) risk. The
primary objective of this study is to investigate
whether provision of a once daily CV FDC (con-
taining aspirin, statin and two blood pressure
lowering agents) in comparison to usual care
(the usual separate and multiple CV medica-
tions prescribed by the treating doctor)
improves adherence to CVD medications and
hence improves the clinical outcomes of blood
pressure and cholesterol. Secondary objectives
include assessment of barriers to medication
adherence, quality of life and comparison of
results between Europe and India. The
UMPIRE trial is funded by the European
Commission Framework Programme 7 and is
led by researchers at Imperial College London
with co-investigators in the Netherlands,
Ireland, India and Australia. The low cost and
simplicity of the FDC strategy is an important
consideration in all economies but particularly
so in India where it has the potential to trans-
form the outlook for CVD prevention. The
UMPIRE trial has recruited 2004 participants
(1000 in India and 1004 in Europe) and
will identify patterns of adherence in the
two treatment groups (FDC and usual care).
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Interpreting the Processes of UMPIRE Trial (INPUT) will
involve a selected subset of participants in the UK and
India. It will provide a qualitative exploration of factors asso-
ciated with different medication adherence patterns
observed within the trial.
Complexity7 and cost8 of regimens are among the
major obstacles for effective management of CVD; these
factors are particularly important in resource-poor
LMIC. A FDC containing CV medications could be a
cost-effective solution to address medication underutil-
isation or non-adherence. A process evaluation will help
to identify any disparities between research and practice
by allowing a detailed examination of the context and
clarifying characteristics of the trial participants and the
local circumstances under which the intervention was
implemented. This insight will identify the moderating
factors that could limit or enhance applicability to
different contexts. The detailed descriptions about
implementation provided by the narratives shared in
semistructured interviews will inform future replication
of the trial and its wider implication by understanding
the scope and limits of generalisability.
Process evaluations complement the ﬁndings from
randomised controlled trial (RCT) investigations. While
RCTs test the effect of intervention(s) on predetermined
outcomes, process evaluations provide insight into the
execution of investigation, the delivery and receipt of
the intervention and the impact of the setting in which
the intervention was delivered.9 In addition, process
evaluations may provide an opportunity to formulate
hypotheses leading to further analysis of the trial data.
METHOD
This study will use an inductive approach to explore the
processes underlying medication adherence to both
FDC and usual care. The method of grounded theory10
will be adopted because of its iterative approach to the
testing of hypotheses emerging from the data, under-
pinned by theoretical literature addressing the recursive
process of reviewing existing literature, sampling, data
collection and analysis.
Literature reviews
Current literature on medication adherence in multiple
disease categories will inform the data collection, with
the analysis and the emerging themes guiding further
in-depth reviews of the literature.
Interviews
Interviews will be undertaken in the UK and India using
a subsample of the UMPIRE trial participants. The total
number of recruits will depend on the consistency of
ﬁndings in the interviews, but a minimum of 50 inter-
views will be carried out (approximately 25 in each trial
arm) within each country to ensure variation across parti-
cipants is in terms of age, gender, treatment arm (includ-
ing those discontinuing FDC) and duration of trial
participation. Recruitment will continue until no new
themes arise from the interviews (thematic saturation).
In addition, local health professionals with expertise
in the ﬁeld of CVD (some who have patients participat-
ing in the UMPIRE trial) will be recruited as key
informants. Key informants will include: general practi-
tioners, practice nurses, cardiologists, neurologists and
pharmacists. Key informants will also be asked to identify
any other professionals they feel would be able to share
their views on the topics under investigation. The inclu-
sion of key informants will provide further insight
into the trial context, how healthcare staff can inﬂuence
patient decisions, and the feasibility of implementing
an FDC strategy for CVD prevention in routine clinical
practice.
In India, as UMPIRE trial visits have occurred across
many different trial sites, a sample of these sites
(approximately 7–9) will be used to recruit participants
and key informants. These sites will be selected to
reﬂect variation across sites in the number of partici-
pants recruited per site, hospital size, hospital setting
(public/private) and site location (geographical and
local language).
Interviews will be semistructured, ensuring that the
same general topics are explored while allowing partici-
pants to lead the direction of discussion and explore in
their own words their views and experiences. Interviewers
will follow a topic guide for both the key informants and
UMPIRE participant interviews in order to ensure con-
sistency in the topics explored during each interview.
The UMPIRE participant interviews will elicit views on
the research process and their individual lifestyle and
routine including:
▸ Their views on the beneﬁts, disadvantages and accept-
ability of their current treatment (FDC or usual care)
▸ Reports on speciﬁc instances where changes occurred
to their usual adherence behaviour and the circum-
stances surrounding these changes
▸ The factors that hinder or facilitate their attitude
towards adherence to therapy within the trial
▸ The factors that would be most likely to make
patients’ adherence behaviour outside the trial situ-
ation differ from that exhibited in the trial
Probing questions will be developed and reﬁned to
explore responses to these broad topics. Key informant
interviews will further contribute to the development of
the topic guide for the UMPIRE participant interviews.
Interviews will be audio recorded, transcribed and anon-
ymised. At the end of each interview, the interviewer will
reﬂect on the content and note the main themes arising
and any relevant remarks about the context of the
interview.
To ensure that similar methods are followed for data
collection and analysis in the UK and India, standard
operating procedures have been written and will be fol-
lowed throughout the study. The researchers will under-
take regular joint supervision with experts in the ﬁelds
of public health, epidemiology, anthropology and CVD.
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Study procedure
At the end of the ﬁnal UMPIRE trial visit, the research
team will invite participants to consider taking part in the
INPUT study and provide a written information sheet.
Those who agree to participate will be asked to give
signed informed consent. Based on the participant’s pref-
erence, interviews will either take place on the same day
as the ﬁnal UMPIRE trial visit or at a later date, either at
the trial centre or at the participant’s home. In India, par-
ticipant interviews will be conducted by interviewers
either in English or in the local languages. The interviews
conducted in the local languages will be translated into
English and then checked for accuracy and anonymised.
After each interview and based on its content, permis-
sion may be sought to take photographs of the partici-
pant’s medications; if the interview is held at their
home, the photograph could include the location where
they usually keep their medications, to gain further
insights into their daily routines. These photographs will
be included as visual sources of qualitative data to con-
tribute to the development and assessment of themes in
the analysis and provide further information about the
context of the trial.11 12
ANALYSIS
The initial data analysis will be carried out independ-
ently for the UK and India. NVivo V.9 qualitative analysis
software will be used to assist with the data management.
Open coding
Initially, line-by-line reading of every interview transcript
will be undertaken, categorising sections of the transcripts
into emergent themes. Repeated reading of the interview
transcripts will assist the reader in viewing the transcript
from different perspectives. Emerging categories will con-
stantly be compared within and between transcripts in an
iterative process. Emergent categories or themes may then
form recognisable patterns that better predict where a situ-
ation or a condition will be more likely to occur. The direc-
tion and quantity of data collection will be guided by these
emerging patterns in the data. Analysis will seek the
repeated presence of speciﬁc content that is present across
a transcript or between participants.
Axial coding
The resulting patterns identiﬁed in the analysis will form
an analytical framework; thematic saturation of the
emerging framework will be reached as the researcher
compares more incidents and ﬁnds fewer differences
arising in patterns. The framework will be considered in
terms of the existing literature, to determine whether
the emerging patterns are well described or novel.
Theoretical sampling
The researchers will seek to establish the conditions
under which the patterns emerging in the analysis
lead to particular outcomes. During INPUT consent
procedures, participants will be asked to agree to pos-
sible follow-up discussion, should particular concepts
need to be explored in more detail or areas clariﬁed.
Additional participants may also be recruited to further
explore topics deemed to be pertinent.
International comparison
After separate analyses have been undertaken for both
the UK and India data, the arising themes will be exam-
ined to identify both common and divergent processes
underlying adherence to the FDC strategy in both data
sets. This comparison will facilitate an understanding of
how different contexts underpin the relevant trial pro-
cesses. The process evaluation will assist interpretation
of results from the trial by examining how far variation
might relate to differences between healthcare systems
and the national context and how these factors impact
trial outcomes.
ETHICS AND DISSEMINATION
Ethics
In the UK and India, the INPUT protocol was approved
by the ethics committees relevant to the participating
UMPIRE trial centres.
Ethical considerations are relevant in all research meth-
odologies, including qualitative designs where areas of
potential harmful to participants may be less apparent.
Richards and Schwartz13 outline four risks to participant’s
well-being during qualitative research involvement—
anxiety and distress, exploitation, misrepresentation and
identiﬁcation of the participant in published reports.
The interviews to be undertaken for INPUTaim to gain
disclosure of personal experience, and therefore the
probing nature of the interviews has the potential to
provoke unforeseen anxiety and distress, especially as
topics that could trigger distress cannot always be pre-
dicted. There is also a risk of exploitation; when a partici-
pant is allowed to speak in their own terms, the interview
can take on the semblance of a therapeutic encounter for
the participant and lead them to disclose more informa-
tion than they initially intended. Further, the interpret-
ation of the participant’s views, such as their behaviour
and beliefs, may be at odds with the participant’s own per-
spective, and reading the published results could itself
have a negative impact on the participant’s sense of self.
During the development of the INPUT protocol,
ethical issues have been considered and, where relevant,
addressed. Although the interviewers will be sensitive
and avoid causing distress to the interviewee as far as
possible, the information sheet will also highlight the
potential risk of distress to the participant from partici-
pation and explicitly note that the interview itself is for
research purposes, although it may also be proﬁtable to
discuss experiences. Standard procedures have also been
established for the management of any participant
who becomes distressed during the interview, and this
includes provision of information and support should it
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be required. Further to this, rigorous analysis procedures
will be followed by the researchers including regular
supervision of the analysis by experienced qualitative
researchers in order to avoid the participant’s views
being misrepresented and to uphold anonymity of data
by considering the multiple clues to identity present in
individual narratives.
Dissemination
As INPUT will use an exploratory method, a plan of
publication will be based on the trial results and the
emerging themes arising from interviews and their sub-
sequent analysis. The process evaluation will also help to
enrich the trial results by exploring and identifying the
key components of the intervention, identifying when
and under what circumstances the intervention is of
beneﬁt, or why the intervention may not have been
favourable. The results of a process evaluation of the
UMPIRE trial will also lead to a better understanding of
the mechanisms involved in adherence to CV medica-
tions in the trial context. Such information will provide
insights into the relevance of a CV FDC strategy in a
clinical context, and may prove useful for designing
effective public health policy with regard to adopting or
rejecting such a strategy. We anticipate that the process
evaluation will explore pertinent factors underlying any
variations in the UMPIRE results between India and the
UK. It will also consider data emerging from parallel
studies within the SPACE collaboration (such as the
process evaluation planned14 for the Kanyini-Gap Trial
in Australia), and comment on variations between the
different settings.
As highlighted, across disease groups, treatment
success is often dependent on successful adherence to
prescribed medications.15 16 Poor adherence is a
complex interplay of several factors.7 Therefore, under-
standing more about the implementation of an FDC
strategy on medicine taking behaviour will also provide
important insight into the determinants of medication
adherence.
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